A cross sectional study assessing the relative impact in Psoriatic arthritis of TNF inhibitors (TNFi) versus non-TNFi bDMARDs on patient reported outcome measures
Latest Information Update: 19 Jun 2021
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Ixekizumab (Primary) ; Secukinumab (Primary) ; Tofacitinib (Primary) ; Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 19 Jun 2021 New trial record
- 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism